Adagio Medical Holdings Inc (ADGM)
ADGM trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2006986/000200698626000003/0002006986-26-000003-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ADGM on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0002006986 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$25.1M |
| Operating income | -$21.9M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $17.1M |
| Total assets | $43.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Management intends to mitigate the conditions and events that raise substantial doubt about the Company's ability to continue as a going concern entity by (i) negotiating other cash equity, debt or strategic financing in the short-term, (ii) continuing to pursue the necessary regulatory approvals to launch commercially in the U.S. market, and (iii) executing cost-cutting measures to manage cash burn." | 10-Q 2026-08-11 |
| Cash and burn | $7.7M cash; operating cash flow -$4.1M a quarter. | Report 2026-06-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-08-10 |
| Reverse splits, 3 years | 1; latest 1-for-30 on 2026-11-09 | Source 2026-11-09 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2025-11-24 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-14 |
| Auditor | WithumSmith+Brown, PC, Whippany, New Jersey, United States | PCAOB Form AP 2026-03-30 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $244K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $0 | -$6.7M | -$5.3M | $7.7M | $24.8M | $0 | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $0 | -$7.0M | -$4.1M | $12.9M | $22.9M | $0 | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $0 | -$3.3M | -$4.1M | $17.1M | $21.0M | $0 | 10-K 2026-03-27 |
| Q3 2025 2025-09-30 | $0 | -$10.1M | -$3.0M | $4.7M | $21.2M | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $0 | -$3.9M | -$4.7M | $8.2M | $16.9M | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $0 | -$7.7M | -$7.2M | $13.0M | $17.7M | Needs four quarters | 10-Q 2026-05-12 |
| Q3 2024 2024-09-30 | Not filed | -$8.2M | Not filed | $28.3M | $13.8M | Needs four quarters | 10-Q 2025-11-12 |
| Q2 2024 2024-06-30 | $254K | -$5.7M | -$6.9M | $2.0M | No debt tags | $399K | 10-Q 2025-08-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-04-02 |
| Latest annual report FORM 10-K/A | 10-K/A | 2026-07-13 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | PRE 14A | 2026-11-10 |
Source: SEC EDGAR submissions feed, 236 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.0% |
| 1 month | -48.5% |
| 3 months | -90.7% |
| Year to date | -93.8% |
| 1 year | -92.1% |
| From 52-week high | -96.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MBOT | Microbot Medical Inc. | $0.6444 | -34.16% | $43.3M |
| MDAI | Spectral AI Inc. | $1.31 | +0.77% | $42.2M |
| DXR | Daxor Corporation | $8.36 | -0.89% | $48.8M |
| SRTS | Sensus Healthcare Inc. | $2.34 | +0.65% | $38.5M |
| TELA | TELA Bio Inc. | $0.7616 | -7.13% | $34.4M |
| NEPH | Nephros Inc. | $3.00 | -1.64% | $32.6M |
| QTEX | QTREX Quantum Ltd. | $1.15 | -8.00% | $64.4M |
| LNSR | LENSAR Inc. | $5.29 | +5.80% | $65.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier